OSE Immunotherapeutics' Tedopi Shows Promise in Ovarian Cancer Trial
Event summary
- TEDOVA Phase 2 trial met primary endpoint, showing statistically significant improvement in progression-free survival (PFS) for Tedopi® + pembrolizumab vs. best supportive care (4.1 months vs. 2.8 months; HR=0.53; p<0.001).
- Trial enrolled 185 patients with platinum-sensitive recurrent ovarian cancer (PSOC) who progressed after or were ineligible for PARP inhibitors and bevacizumab.
- Results to be presented at ASCO 2026 Annual Meeting on May 30, 2026, by Lead Investigator Alexandra Leary, MD, PhD.
- KOL webcast scheduled for June 10, 2026, to discuss Tedopi®'s potential in multiple oncology indications.
The big picture
The positive results from the TEDOVA trial represent a significant milestone for OSE Immunotherapeutics, providing clinical validation for Tedopi® as a potential maintenance treatment in recurrent ovarian cancer. This success underscores the growing interest in immuno-oncology combination therapies and positions OSE Immunotherapeutics to advance Tedopi® into Phase 3 development. The company's strategy to leverage academic collaborations for further clinical exploration highlights its focus on addressing unmet medical needs in difficult-to-treat cancers.
What we're watching
- Clinical Validation
- Whether the positive Phase 2 results will translate into successful Phase 3 trials for Tedopi® in non-small cell lung cancer and other indications.
- Combination Strategies
- The pace at which OSE Immunotherapeutics advances investigator-sponsored trials combining Tedopi® with other therapies in ovarian, pancreatic, and lung cancers.
- Regulatory Pathway
- How the company navigates regulatory requirements for Tedopi®'s approval in multiple oncology indications.
Related topics